



DIASORIN LAUNCHES ELASTASE-1 TEST FOR THE DIAGNOSIS OF CHRONIC EXOCRINE PANCREATITIS ON LIAISON XL

May 6, 2019 – DiaSorin (FTSE MIB: DIA) announced the launch in the CE market of the Elastase-1 quantification test to support the diagnosis of chronic exocrine pancreatitis on the automated LIAISON XL platform. The test, the first in the world on CLIA technology, is also available in the US.

This pathology is a condition of chronic inflammation of the exocrine apparatus of the pancreas that causes pain and loss of normal organ function. In the condition of exocrine pancreatic insufficiency, the low quantity of pancreatic digestive enzymes leads to situations of poor digestion and poor absorption of ingested food.

According to available epidemiological data, chronic exocrine pancreatitis is classified as a pathology with contained incidence for which an early diagnosis and monitoring of the course of the acute to chronic disease is difficult.

"Our commitment continues to expand the panel to support the diagnosis and treatment of digestive tract diseases: the Elastase-1 test is the first diagnostic tool on CLIA technology available worldwide on our LIAISON XL platforms." commented Carlo Rosa, CEO of the DiaSorin Group. *"The launch of this new test confirms our vocation: to support our customers and meet the needs of laboratories around the world with innovative and automated assays."*

DiaSorin

Headquartered in Italy and listed in the FTSE MIB Index, DiaSorin is a global leader in the In Vitro Diagnostic (IVD) field. For over 50 years, the Company has been developing, producing and marketing reagent kits for IVD worldwide. The Group has a presence on the 5 continents with 25 companies, 5 foreign branches, 6 manufacturing facilities and 5 research centers throughout the world. Through constant investments in research and development, and using its own distinctive expertise in the field of immunodiagnosics to deliver a high level of innovation, DiaSorin offers today the broadest range of specialty tests available in the immunodiagnosics market and new tests in the molecular diagnostics markets, which identify DiaSorin Group as the "Diagnostic Specialist".

For additional information, please contact:

Riccardo Fava

Corporate Vice President Communication & Investor Relations

Tel: +39.0161.487988

riccardo.fava@diasorin.it

Ines Di Terlizzi

Investor Relator

Tel: +39.0161.487567

ines.diterlizzi@diasorin.it